SG11201907308UA - Pharmaceutical combination comprising ponesimod - Google Patents

Pharmaceutical combination comprising ponesimod

Info

Publication number
SG11201907308UA
SG11201907308UA SG11201907308UA SG11201907308UA SG11201907308UA SG 11201907308U A SG11201907308U A SG 11201907308UA SG 11201907308U A SG11201907308U A SG 11201907308UA SG 11201907308U A SG11201907308U A SG 11201907308UA SG 11201907308U A SG11201907308U A SG 11201907308UA
Authority
SG
Singapore
Prior art keywords
international
ponesimod
allschwil
pct
teriflunomide
Prior art date
Application number
SG11201907308UA
Inventor
Martine Clozel
Laetitia Pouzol
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of SG11201907308UA publication Critical patent/SG11201907308UA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

International Patent Classification: A61K 31/426 (2006.01) A61P 25/00 (2006.01) A61K 31/277 (2006.01) A61P 37/00 (2006.01) A61K 31/42 (2006.01) A61P 37/06 (2006.01) (21) International Application Number: (54) Title: PHARMACEUTICAL COMBINATION COMPRISING PONESIMOD Fig. 1 - 0- Vehicle 10 Teriflunomide 1 mg/kg --e- Ponesimod 30 mg/kg - Teriflunomide 1 mg/kg + Ponesimod 30 mg/kg Clin ica l Sco re ( Averag e a n d SEM) O (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 20 September 2018 (20.09.2018) WIPO I PCT Hu omit VIII °nolo omioomominomo oimIE (10) International Publication Number WO 2018/167030 Al PCT/EP2018/056185 (22) International Filing Date: 13 March 2018 (13.03.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: PCT/EP2017/055994 14 March 2017 (14.03.2017) EP (71) Applicant: ACTELION PHARMACEUTICALS LTD [CH/CH]; Gewerbestrasse 16, 4123 Allschwil (CH). (72) Inventors: CLOZEL, Martine; c/o Idorsia Pharmaceuti- cals Ltd Hegenheimermattweg 91, 4438 Allschwil (CH). POUZOL, Laetitia; c/o Idorsia Pharmaceuticals Ltd Hegenheimermattweg 91, 4123 Allschwil (CH). (74) Agent: GSCHWEND, Thomas; Gewerbestrasse 16, 4123 Allschwil (CH). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). 0 5 10 15 20 N 1-1 00 (57) : The present invention relates to a pharmaceutical combination comprising a first active ingredient which is ponesimod 0 and a second active ingredient which is selected from the group consisting of teriflunomide and leflunomide. o [Continued on next page] Day of treatment WO 2018/167030 Al MIDEDIMOMMIDIREEMOMOHIMEIMEMIHMEHOIMI Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(H)) Published: — with international search report (Art. 21(3))
SG11201907308UA 2017-03-14 2018-03-13 Pharmaceutical combination comprising ponesimod SG11201907308UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2017055994 2017-03-14
PCT/EP2018/056185 WO2018167030A1 (en) 2017-03-14 2018-03-13 Pharmaceutical combination comprising ponesimod

Publications (1)

Publication Number Publication Date
SG11201907308UA true SG11201907308UA (en) 2019-09-27

Family

ID=61655772

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201907308UA SG11201907308UA (en) 2017-03-14 2018-03-13 Pharmaceutical combination comprising ponesimod

Country Status (24)

Country Link
US (1) US11723896B2 (en)
EP (1) EP3595657A1 (en)
JP (2) JP7281406B2 (en)
KR (1) KR102574562B1 (en)
CN (1) CN110381942B (en)
AU (2) AU2018233109B2 (en)
BR (1) BR112019018894A2 (en)
CA (1) CA3056301A1 (en)
CL (1) CL2019002525A1 (en)
CO (1) CO2019008510A2 (en)
CR (1) CR20190464A (en)
DO (1) DOP2019000257A (en)
EA (1) EA201992117A1 (en)
EC (1) ECSP19073317A (en)
IL (1) IL269239B2 (en)
JO (1) JOP20190207A1 (en)
MA (1) MA49822A (en)
MX (1) MX2019010874A (en)
NI (1) NI201900092A (en)
PE (1) PE20191489A1 (en)
PH (1) PH12019502110A1 (en)
SG (1) SG11201907308UA (en)
UA (1) UA125756C2 (en)
WO (1) WO2018167030A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11186556B1 (en) 2018-10-16 2021-11-30 Celgene Corporation Salts of a thiazolidinone compound, solid forms, compositions and methods of use thereof
US11014940B1 (en) 2018-10-16 2021-05-25 Celgene Corporation Thiazolidinone and oxazolidinone compounds and formulations
US11013723B1 (en) 2018-10-16 2021-05-25 Celgene Corporation Solid forms of a thiazolidinone compound, compositions and methods of use thereof
US11014897B1 (en) 2018-10-16 2021-05-25 Celgene Corporation Solid forms comprising a thiazolidinone compound, compositions and methods of use thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL178596C (en) 1975-06-05 1986-04-16 Hoechst Ag METHOD FOR PREPARING A MEDICINAL PRODUCT WITH ANTIFLOGISTIC AND / OR ANALGETIC ACTION, AND A METHOD FOR PREPARING THEIR PRODUCT TO BE USED AS MEDICINAL COMPOUNDS 5-METHYLISOXAZOLE-4-CARBONIC ACID.
DE2854439A1 (en) 1978-12-16 1980-07-03 Hoechst Ag AN ISOXAZOLE DERIVATIVE, METHOD FOR THE PRODUCTION THEREOF, AGENT AND USE THEREOF
US5268382A (en) 1985-09-27 1993-12-07 Hoechst Aktiengesellschaft Medicaments to combat autoimmune diseases, in particular systemic lupus erythematosus
DE3534440A1 (en) 1985-09-27 1987-04-02 Hoechst Ag DRUGS AGAINST CHRONIC GRAFT VERSUS HOST DISEASES AND AUTO AUTO DISEASES, IN PARTICULAR SYSTEMIC LUPUS ERYTHEMATODES
DE60110043T2 (en) 2000-02-15 2006-03-02 Teva Pharmaceutical Industries Ltd. METHOD FOR SYNTHETIZING LEFLUNOMID
GB0123571D0 (en) * 2001-04-05 2001-11-21 Aventis Pharm Prod Inc Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis
WO2002080897A1 (en) 2001-04-05 2002-10-17 Aventis Pharmaceuticals Inc. Use of (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis
US6894184B2 (en) 2003-03-18 2005-05-17 Aventis Pharma Deutschland Gmbh Process for preparing 2-cyano-3-hydroxy-N-(phenyl)but-2-enamides
CA2545582C (en) 2003-11-21 2013-04-16 Actelion Pharmaceuticals Ltd 5-(benz-(z)-ylidene)-thiazolidin-4-one derivatives as immunosuppressant agents
USRE43833E1 (en) 2003-11-21 2012-11-27 Actelion Pharmaceuticals Ltd. Thiazolidin-4-one derivatives
AU2005295511A1 (en) 2004-10-19 2006-04-27 Aventis Pharmaceuticals Inc. Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating inflammatory bowel disease
DE102006017896A1 (en) 2006-04-13 2007-10-25 Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher Gmbh & Co. Kg Leflunomide-containing pharmaceutical compositions
ES2410793T3 (en) 2006-11-23 2013-07-03 Actelion Pharmaceuticals Ltd. New procedure for the preparation of 2-imino-thiazolidin-4-one derivatives
US8912340B2 (en) 2006-11-23 2014-12-16 Actelion Pharmaceuticals Ltd. Process for the preparation of 2-imino-thiazolidin-4-one derivatives
JP4846063B2 (en) 2008-03-17 2011-12-28 アクテリオン ファーマシューティカルズ リミテッド Administration method of selective S1P1 receptor agonist
GB0819182D0 (en) 2008-10-20 2008-11-26 Actelion Pharmaceuticals Ltd Crystalline forms
EP2477611B1 (en) 2009-09-18 2017-04-05 Sanofi (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability
JP2013533286A (en) 2010-07-30 2013-08-22 セントルイス ユニバーシティ How to treat pain
AR082436A1 (en) 2010-08-02 2012-12-05 Sanofi Aventis Us Llc USE OF TERIFLUNOMIDE TO TREAT MULTIPLE SCLEROSIS
EP2692343A1 (en) 2012-08-03 2014-02-05 Forward Pharma A/S Combination therapy for treatment of multiple sclerosis
HUE050733T2 (en) 2012-08-17 2021-01-28 Actelion Pharmaceuticals Ltd Process for the preparation of (2z,5z)-5-(3-chloro-4-((r)-2,3-dihydroxypropoxy)benzylidene)-2-(propylimino)-3-(o-tolyl)thiazolidin-4-one and intermediate used in said process
WO2016079687A1 (en) 2014-11-18 2016-05-26 Lupin Limited Oral pharmaceutical composition of teriflunomide
MA41139A (en) 2014-12-11 2017-10-17 Actelion Pharmaceuticals Ltd PHARMACEUTICAL COMBINATION INCLUDING A SIP1 RECEPTOR SELECTIVE AGONIST
LT3256125T (en) * 2014-12-11 2022-04-11 Actelion Pharmaceuticals Ltd Dosing regimen for ponesimod, a selective s1p1 receptor agonist
WO2016205654A1 (en) 2015-06-18 2016-12-22 Aquarius Biotechnologies, Inc. Compositions and methods for treating inflammatory disease or conditions

Also Published As

Publication number Publication date
US11723896B2 (en) 2023-08-15
IL269239B1 (en) 2023-03-01
EA201992117A1 (en) 2020-02-17
JP2023030091A (en) 2023-03-07
PH12019502110A1 (en) 2020-03-16
PE20191489A1 (en) 2019-10-21
UA125756C2 (en) 2022-06-01
JP2020510045A (en) 2020-04-02
DOP2019000257A (en) 2020-09-15
IL269239A (en) 2019-11-28
JP7281406B2 (en) 2023-05-25
CN110381942A (en) 2019-10-25
EP3595657A1 (en) 2020-01-22
ECSP19073317A (en) 2019-11-30
JOP20190207A1 (en) 2019-09-10
CL2019002525A1 (en) 2020-02-07
AU2023274118A1 (en) 2023-12-21
AU2018233109A1 (en) 2019-08-22
WO2018167030A1 (en) 2018-09-20
CN110381942B (en) 2022-12-27
NI201900092A (en) 2020-03-11
BR112019018894A2 (en) 2020-04-14
AU2018233109B2 (en) 2023-09-28
MA49822A (en) 2020-06-17
US20200069655A1 (en) 2020-03-05
CO2019008510A2 (en) 2019-10-21
CR20190464A (en) 2019-11-26
KR20190122716A (en) 2019-10-30
MX2019010874A (en) 2019-12-11
CA3056301A1 (en) 2018-09-20
IL269239B2 (en) 2023-07-01
KR102574562B1 (en) 2023-09-04

Similar Documents

Publication Publication Date Title
SG11201908330PA (en) Farnesoid x receptor agonists and uses thereof
SG11201907604UA (en) Crystalline forms of the 4-pyrimidinesulfamide derivative aprocitentan
SG11201907034PA (en) Methods of treating influenza
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201900349VA (en) Somatostatin modulators and uses thereof
SG11201807784SA (en) 3-desoxy derivative and pharmaceutical compositions thereof
SG11201907308UA (en) Pharmaceutical combination comprising ponesimod
SG11201907804QA (en) Pharmaceutical composition comprising selexipag
SG11201908512YA (en) Somatostatin modulators and uses thereof
SG11201809908TA (en) Stabilized glycopeptide antibiotic formulations
SG11201808713YA (en) Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier
SG11201903061YA (en) Combination treatments comprising administration of imidazopyrazinones
SG11201900554YA (en) Spiro-lactam nmda modulators and methods of using same
SG11201807827VA (en) Process for the preparation of pegylated drug-linkers and intermediates thereof
SG11201900558RA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201809751XA (en) Egfr inhibitor compounds
SG11201809882XA (en) Pharmaceutical combinations for treating cancer
SG11201900551WA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201806393QA (en) Use of gabaa receptor modulators for treatment of itch
SG11201900546UA (en) Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
SG11201901438VA (en) Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate
SG11201806133UA (en) Intermediates in the synthesis of eribulin and related methods of synthesis
SG11201901063SA (en) Therapeutic agents for neurodegenerative diseases
SG11201804587QA (en) Isoindole compounds
SG11201908325PA (en) Process for the preparation of glucuronide drug-linkers and intermediates thereof